MedPath
FDA Approval

Regadenoson

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Hospira, Inc.
DUNS: 141588017
Effective Date
March 2, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Regadenoson(0.08 mg in 1 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Hospira, Inc.

Hospira, Inc.

093132819

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Regadenoson

Product Details

NDC Product Code
0409-1401
Application Number
ANDA214349
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
March 2, 2023
Code: 7AXV542LZ4Class: ACTIBQuantity: 0.08 mg in 1 mL
SODIUM PHOSPHATE, DIBASIC, ANHYDROUSInactive
Code: 22ADO53M6FClass: IACTQuantity: 8.7 mg in 1 mL
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATEInactive
Code: 593YOG76RNClass: IACTQuantity: 5.4 mg in 1 mL
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3Class: IACTQuantity: 150 mg in 1 mL
EDETATE DISODIUMInactive
Code: 7FLD91C86KClass: IACTQuantity: 1 mg in 1 mL
WATERInactive
Code: 059QF0KO0RClass: IACT
© Copyright 2025. All Rights Reserved by MedPath
Regadenoson - FDA Approval | MedPath